Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 25, 2005. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, rather than a comprehensive financial results report.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the share price of GBP14.54 per share, which was the price at which dividends were re-invested under the GlaxoSmithKline Annual Investment Plan.
Material Changes
The filing details an increase in shareholdings for specific individuals following the re-investment of dividends paid on October 6, 2005. The specific increases are:
- Mr R Bondy: 180 shares
- Mr M Dunoyer: 67 shares
- Dr D Pulman: 102 shares
- Mrs J Younger: 156 shares
- Mr A Witty: 62 shares
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a regulatory disclosure of insider share transactions pursuant to Disclosure Rule 3.1.4R(1)(a).
Investor Verification Checklist
- Verify the total number of shares held by the listed directors prior to this transaction to assess total ownership concentration.
- Confirm the dividend amount per share paid on October 6, 2005, to validate the calculation of shares acquired at GBP14.54.
- Review the company's Form 20-F for the full fiscal year to obtain comprehensive financial performance data not included in this 6-K.